Oncolytics Biotech, Inc. (ONCY)
0.81
-0.03
(-3.57%)
USD |
NASDAQ |
Jun 09, 15:32
Oncolytics Biotech SG&A Expense (Quarterly) : 4.729M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Replimune Group, Inc. | 18.73M |
| Arrowhead Pharmaceuticals, Inc. | 41.74M |
| Sangamo Therapeutics, Inc. | 6.818M |
| Sarepta Therapeutics, Inc. | 108.95M |
| Anixa Biosciences, Inc. | 1.614M |